"We don’t have long enough follow-up to know what those complete responses mean in terms of long-term survival. It is a phase I trial, but to see these kinds of responses in an AML refractory population with a selective drug against a mutated target, it’s a sign that there are some pretty exciting things happening in oncology these days."
Agios Pharmaceuticals funded the study. Dr. Stein disclosed that he has been a consultant for Janssen.